Scarica l'app Stockscreener
2.69
3.86%
0.10
Pre-mercato:
2.73
0.04
+1.49%
Precedente Chiudi:
$2.59
Aprire:
$2.59
Volume 24 ore:
3.20M
Relative Volume:
1.09
Capitalizzazione di mercato:
$386.50M
Reddito:
$4.21M
Utile/perdita netta:
$-97.67M
Rapporto P/E:
-2.8925
EPS:
-0.93
Flusso di cassa netto:
$-70.76M
1 W Prestazione:
-2.54%
1M Prestazione:
-1.47%
6M Prestazione:
-0.74%
1 anno Prestazione:
-9.43%
Intervallo 1D:
$2.535
$2.715
Intervallo di 1 settimana:
$2.49
$2.79
Portata 52W:
$2.01
$6.33
Absci Corp Stock (ABSI) Company Profile
Nome
Absci Corp
Settore
Industria
Telefono
(360) 949-1041
Indirizzo
18105 SE MILL PLAIN BLVD, VANCOUVER
Confronta ABSI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABSI
Absci Corp
|
2.69 | 386.50M | 4.21M | -97.67M | -70.76M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Absci Corp Stock (ABSI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-22 | Iniziato | Needham | Buy |
| 2024-10-02 | Iniziato | Guggenheim | Buy |
| 2024-07-03 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-07-18 | Iniziato | Truist | Buy |
| 2022-03-02 | Ripresa | Cowen | Market Perform |
| 2022-02-01 | Iniziato | Berenberg | Buy |
| 2021-11-10 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-10-15 | Ripresa | Cowen | Market Perform |
| 2021-08-16 | Iniziato | BofA Securities | Neutral |
| 2021-08-16 | Iniziato | Cowen | Market Perform |
| 2021-08-16 | Iniziato | Credit Suisse | Outperform |
| 2021-08-16 | Iniziato | Stifel | Hold |
Mostra tutto
Absci Corp Borsa (ABSI) Ultime notizie
Millennium Management LLC Sells 1,149,603 Shares of Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Co. (NASDAQ:ABSI) Given Average Rating of "Buy" by Brokerages - MarketBeat
Transcript : Absci Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - marketscreener.com
Two Sigma Investments LP Raises Stock Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Deutsche Bank AG Purchases 28,073 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
Absci (NASDAQ:ABSI) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Top 5 AI & Digital Biotech Companies (June 2025) - Securities.io
Absci (NASDAQ:ABSI) Stock Rating Lowered by Wall Street Zen - Defense World
AbSci Corp (ABSI) Sees Borrow Rate Increase | ABSI Stock News - GuruFocus
Woodline Partners LP Decreases Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Northern Trust Corp Has $1.72 Million Stock Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Brokerages Set Absci Co. (NASDAQ:ABSI) Price Target at $8.40 - MarketBeat
Wall Street Zen Upgrades Absci (NASDAQ:ABSI) to Hold - Defense World
Ameriprise Financial Inc. Sells 23,668 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
AbSci Corp (ABSI): Key Indicator Shows Noticeable Increase | ABSI Stock News - GuruFocus
Catherine Wood's Strategic Acquisition of Absci Corp Shares - GuruFocus
Schonfeld Strategic Advisors LLC Has $144,000 Stake in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci to Participate in Upcoming Investor Conferences - GlobeNewswire
Absci Sets Stage for Major AI Breakthroughs at Goldman Sachs and Jefferies Healthcare Conferences - Stock Titan
Needham & Company LLC Reiterates Buy Rating for Absci (NASDAQ:ABSI) - MarketBeat
Price T Rowe Associates Inc. MD Increases Holdings in Absci Co. (NASDAQ:ABSI) - Defense World
Absci Co. (NASDAQ:ABSI) Shares Sold by Stifel Financial Corp - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Absci (NASDAQ:ABSI) - Defense World
Absci Corp’s Earnings Call: A Promising Outlook - TipRanks
Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript - Insider Monkey
Absci First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI) - Defense World
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI Stock News - GuruFocus
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 | ABSI Stock News - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101 - GuruFocus
ABSI: Needham Reiterates Buy Rating and $9 Price Target | ABSI S - GuruFocus
Assessing Absci: Insights From 6 Financial Analysts - Benzinga
Why Everus Construction Group Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Absci Corporation Advances Clinical Programs with Strong Q1 Results - TipRanks
Fred Alger Management LLC Reduces Position in Absci Co. (NASDAQ:ABSI) - MarketBeat
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Reve - GuruFocus
Absci earnings beat by $0.01, revenue fell short of estimates - Investing.com
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings By Investing.com - Investing.com Nigeria
AbSci (ABSI) Anticipates Significant Post-Earnings Movement | AB - GuruFocus
Earnings call transcript: Absci Q1 2025 sees stock surge post-earnings - Investing.com
Absci Q1 2025 Earnings Call Transcript - MarketBeat
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Absci Corp reports results for the quarter ended March 31Earnings Summary - TradingView
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiat - GuruFocus
ABSI Surprises with Q1 Revenue Beat and Expands Clinical Initiatives | ABSI Stock News - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial - TipRanks
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results - GlobeNewswire
Absci Announces First Participants Dosed In Phase 1 Clinical Trial Of Abs-101, A Potential Best-In-Class Anti-TL1a Antibody For The Treatment Of Inflammatory Bowel Disease - marketscreener.com
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease - GlobeNewswire
Breakthrough: First-Ever AI-Designed IBD Treatment Begins Human Trials with Quarterly Dosing Potential - Stock Titan
What To Expect From Absci Corp (ABSI) Q1 2025 Earnings - GuruFocus
Absci Corp Azioni (ABSI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):